StockData

Agios Pharmaceuticals vs Cytokinetics

AGIO and CYTK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AGIO and CYTK compare

Agios Pharmaceuticals is the larger company, worth 272 times as much as Cytokinetics ($1.8B against $6.6M).

Agios Pharmaceuticals grew revenue faster over the last twelve months (141% versus −21.1% for Cytokinetics).

Agios Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −418% compared with −1321% at Cytokinetics.

Agios Pharmaceuticals scores higher on the StockData Score (12 against 4 for Cytokinetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAGIOCYTK
Size and price
Market cap$1.8B$6.6M
Share price$30.15$53.17
Change, 1 year−29.1%−18.8%
Change, 5 years−17.3%36.2%
Beta (5Y)1.531.08
Employees539673
StockData Score
Total score12 (better)4
Valuation score11
Growth score3 (better)1
Performance score2 (better)1
Health score6 (better)1
Dividend score00
Valuation
P/S18.3×0.1× (better)
P/B1.8×–
FCF yield−20.3% (better)−8776%
Fair value$27.48–
Margin of safety−9.7%–
Growth
Revenue growth (TTM)141% (better)−21.1%
Revenue growth, 5Y average–9.5%
Net income growth (TTM)−163%–
EPS growth (TTM)−163%–
Profitability
Gross margin92.0%–
Operating margin−467% (better)−1046%
Net margin−418% (better)−1321%
FCF margin−371% (better)−858%
Return on equity−34.3%–
Return on invested capital−759%–
Financial health
Debt / equity0.00–
Current ratio10.22 (better)6.66
Altman Z-score11.57 (better)−3.37
Piotroski F-score12 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions111%115%
Held by insiders1.1%0.68%
Insider net buying, 12 months−$4.9M (better)−$51.5M
Short interest, % of float11.1%13.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.